Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiation Therapy Combined With Carelizumab for Advanced HCC
NCT04193696Phase 2Unknown
- Sponsor
- Guangxi Medical University
- Start
- Jan 2020
- Primary completion
- Jun 2020
- Modality
- Immune Checkpoint Inhibitors
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab in hepatocellular carcinoma (HCC), sponsored by Guangxi Medical University. Primary endpoint: Objective Response Rate at 6 months. Status: unknown.
02
Drugs
camrelizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04193696.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04193696.